These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34821179)

  • 1. Noninvasive urine metabolomics of prostate cancer and its therapeutic approaches: a current scenario and future perspective.
    Kumar D; Nath K; Lal H; Gupta A
    Expert Rev Proteomics; 2021 Nov; 18(11):995-1008. PubMed ID: 34821179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of emerging metabolomics-based biomarkers of prostate cancer: a systematic review.
    Bansal N; Kumar M; Sankhwar SN; Gupta A
    Expert Rev Mol Med; 2022 Jun; 24():e25. PubMed ID: 35730322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics and Proteomics in Prostate Cancer Research: Overview, Analytical Techniques, Data Analysis, and Recent Clinical Applications.
    Al-Daffaie FM; Al-Mudhafar SF; Alhomsi A; Tarazi H; Almehdi AM; El-Huneidi W; Abu-Gharbieh E; Bustanji Y; Alqudah MAY; Abuhelwa AY; Guella A; Alzoubi KH; Semreen MH
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
    Kumar D; Gupta A; Mandhani A; Sankhwar SN
    Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
    Gupta A; Nath K; Bansal N; Kumar M
    Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Bruzzone C; Loizaga-Iriarte A; Sánchez-Mosquera P; Gil-Redondo R; Astobiza I; Diercks T; Cortazar AR; Ugalde-Olano A; Schäfer H; Blanco FJ; Unda M; Cannet C; Spraul M; Mato JM; Embade N; Carracedo A; Millet O
    J Proteome Res; 2020 Jun; 19(6):2419-2428. PubMed ID: 32380831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
    Dudka I; Thysell E; Lundquist K; Antti H; Iglesias-Gato D; Flores-Morales A; Bergh A; Wikström P; Gröbner G
    BMC Cancer; 2020 May; 20(1):437. PubMed ID: 32423389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.
    Burton C; Ma Y
    Curr Med Chem; 2019; 26(1):5-28. PubMed ID: 28914192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomics of prostate cancer: Knock-in versus knock-out prostate.
    Kumar D; Bansal N; Gupta A; Mandhani A; Lal H; Kumar M; Sankhwar SN
    J Pharm Biomed Anal; 2021 Oct; 205():114333. PubMed ID: 34461489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of prostate cancer tissue metabolomics: would clinics utilise it for diagnosis?
    Bansal N; Kumar M; Sankhwar SN; Gupta A
    Expert Rev Mol Med; 2023 Aug; 25():e26. PubMed ID: 37548191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.
    Yang B; Liao GQ; Wen XF; Chen WH; Cheng S; Stolzenburg JU; Ganzer R; Neuhaus J
    J Zhejiang Univ Sci B; 2017 Nov.; 18(11):921-933. PubMed ID: 29119730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomics-derived prostate cancer biomarkers: fact or fiction?
    Kumar D; Gupta A; Mandhani A; Sankhwar SN
    J Proteome Res; 2015 Mar; 14(3):1455-64. PubMed ID: 25609016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomics in noninvasive breast cancer.
    Zhang AH; Sun H; Qiu S; Wang XJ
    Clin Chim Acta; 2013 Sep; 424():3-7. PubMed ID: 23669185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study.
    Röhnisch HE; Kyrø C; Olsen A; Thysell E; Hallmans G; Moazzami AA
    BMC Med; 2020 Jul; 18(1):187. PubMed ID: 32698845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
    Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Prostate Cancer Noninvasive Biomarker Screening Using Segmented Flow Mass Spectrometry-Based Untargeted Metabolomics.
    Pinto FG; Mahmud I; Harmon TA; Rubio VY; Garrett TJ
    J Proteome Res; 2020 May; 19(5):2080-2091. PubMed ID: 32216312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data-Driven Soft Independent Modeling of Class Analogy in Paper Spray Ionization Mass Spectrometry-Based Metabolomics for Rapid Detection of Prostate Cancer.
    Pinto FG; Mahmud I; Rubio VY; Máquina ADV; Furtado Durans AF; Neto WB; Garrett TJ
    Anal Chem; 2022 Feb; 94(4):1925-1931. PubMed ID: 35060703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomics of lung cancer: Analytical platforms and their applications.
    Noreldeen HAA; Liu X; Xu G
    J Sep Sci; 2020 Jan; 43(1):120-133. PubMed ID: 31747121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The applications of metabolomics in the molecular diagnostics of cancer.
    Cheung PK; Ma MH; Tse HF; Yeung KF; Tsang HF; Chu MKM; Kan CM; Cho WCS; Ng LBW; Chan LWC; Wong SCC
    Expert Rev Mol Diagn; 2019 Sep; 19(9):785-793. PubMed ID: 31414918
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.